<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01801319</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-07</org_study_id>
    <secondary_id>Health Canada 148956</secondary_id>
    <nct_id>NCT01801319</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression</brief_title>
  <official_title>A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled double-blind cross-over trial evaluating the safety,&#xD;
      efficacy, daily functioning, and health-related quality of life of Subcallosal Cingulate&#xD;
      Gyrus Deep Brain Stimulation (SCG DBS) for participants with Treatment-Resistant Depression&#xD;
      (TRD). A total of 40 eligible participants will be randomized to four treatment sequences (10&#xD;
      participants per sequence). Each participant will be treated over a 6-month period with&#xD;
      active or sham stimulation in which both the participants and the attending psychiatrists&#xD;
      will be blinded to treatment allocation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy: Changes in the Hamilton Depression Rating Scale-17</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>evaluate change in HAMD-17 3 months and 6 months after implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of all adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>The incidence of all adverse events (i.e. hospitalization due to worsening depression, suicidal ideation, or behavior, medical treatment, and device related events) that occur over study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Showing SCG-DBS significantly increases health related quality of life compared to sham stimulation in patients with TRD</measure>
    <time_frame>6 months</time_frame>
    <description>The following health related quality of life measures will be evaluated: Sheehan Disability Scale-Visual Analog Scale (SDS-VAS), Short Form-12 (SF-12), Sexual Functioning questionnaire (SEX FX) and Endicott Work Productivity Scale (EWPS). Each measure will be evaluated at baseline and the after each treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Libra Deep Brain Stimulation System is implanted and activated post implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Libra DBS System is implanted and not activated</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Libra Deep Brain Stimulation System</intervention_name>
    <arm_group_label>No Stimulation</arm_group_label>
    <arm_group_label>Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women (non-pregnant) ages 21-70 years;&#xD;
&#xD;
          2. Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by&#xD;
             DSM-IV-TR criteria;&#xD;
&#xD;
          3. First episode onset before age 45;&#xD;
&#xD;
          4. Current episode &gt; 12 months duration;&#xD;
&#xD;
          5. In the current episode: Documented resistance (i.e. persistence of the major&#xD;
             depressive episode) to a minimum of 4 adequate depression treatments from at least 3&#xD;
             different treatment categories (e.g. SSRI's, SNRI's, TCA's, MAO-inhibitors,&#xD;
             Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid&#xD;
             augmentation, ECT); Adequacy of treatments as defined by a score of at least 3&#xD;
             according to the amended Antidepressant Treatment History Form (ATHF) criteria;&#xD;
&#xD;
          6. Hamilton Depression Rating Scale (HDRS) of &gt; 20 at 3 separate baseline visits, rated&#xD;
             by 2 separate psychiatrists, Baseline 2 and Baseline 3 HDRS scores cannot improve â‰¥&#xD;
             25%;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria;&#xD;
&#xD;
          2. Meets criteria for borderline or antisocial personality disorder in the last 12 months&#xD;
             by DSM-IV-TR criteria, derived from the Cluster B Personality.&#xD;
&#xD;
          3. In the current depressive episode, has been diagnosed with General Anxiety Disorder&#xD;
             (GAD) - as defined by the DSM-IV-TR, and GAD is the primary diagnosis;&#xD;
&#xD;
          4. Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory&#xD;
             or cognitive function or that requires intermittent or chronic medication (e.g.,&#xD;
             Parkinson's Disease, migraine, stroke, Huntington's, head trauma, etc.) with exception&#xD;
             to non-migraine headaches;&#xD;
&#xD;
          5. Has been diagnosed with fibromyalgia or has a current condition which requires chronic&#xD;
             pain narcotic usage (e.g. morphine, methadone);&#xD;
&#xD;
          6. Has been currently diagnosed with chronic fatigue syndrome;&#xD;
&#xD;
          7. Substantial suicidal risk as defined by (1) a current plan and intent, (2) clinician&#xD;
             judgment that there is a clear immediate intent for self-harm, (3) more than 3 suicide&#xD;
             attempts within the last 12 months;&#xD;
&#xD;
          8. Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic&#xD;
             disorder, bulimia or anorexia nervosa if previously present, must be in remission for&#xD;
             6 months as defined by DSM-IV-TR criteria, derived from the MINI;&#xD;
&#xD;
          9. Alcohol, medication, or illegal substance dependence within last 12 months;&#xD;
&#xD;
         10. Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as&#xD;
             determined by neurosurgeon;&#xD;
&#xD;
         11. Plans to use diathermy;&#xD;
&#xD;
         12. Have any metallic implants in the brain such as aneurysm clips or cochlear implants;&#xD;
&#xD;
         13. Currently participating in another investigational device, drug or surgical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sidney Kennedy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>February 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>major depressive disorder (MDD)</keyword>
  <keyword>deep brain stimulation (DBS)</keyword>
  <keyword>subcallosal cingulate gyrus</keyword>
  <keyword>Therapy-Resistant Depression</keyword>
  <keyword>Electrical Stimulation of the Brain</keyword>
  <keyword>Brain Stimulation, Deep</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

